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Abstract The Simian immunodeficiency virus (SIV)-
infected Indian rhesus macaque (Macaca mulatta)i st h e
most established model of HIV infection and AIDS-related
research, despite the potential that macaques of Chinese
origin is a more relevant model. Ongoing efforts to further
characterize the Chinese rhesus macaques’ major histocom-
patibility complex (MHC) for composition and function
should facilitate greater utilization of the species. Previous
studies have demonstrated that Chinese-origin M. mulatta
(Mamu) class I alleles are more polymorphic than their
Indian counterparts, perhaps inferring a model more repre-
sentative of human MHC, human leukocyte antigen (HLA).
Furthermore, the Chinese rhesus macaque class I allele
Mamu-A1*02201, the most frequent allele thus far identi-
fied, has recently been characterized and shown to be an
HLA-B7 supertype analog, the most frequent supertype in
human populations. In this study, we have characterized two
additional alleles expressed with high frequency in Chinese
rhesus macaques, Mamu-A1*02601 and Mamu-B*08301.
Upon the development of MHC–peptide-binding assays and
definition of their associated motifs, we reveal that these
Mamu alleles share peptide-binding characteristics with the
HLA-A2 and HLA-A3 supertypes, respectively, the next
most frequent human supertypes after HLA-B7. These data
suggest that Chinese rhesus macaques may indeed be a more
representative model of HLA gene diversity and function as
compared to the species of Indian origin and therefore a
better model for investigating human immune responses.
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Rhesus macaque
Introduction
Non-human primates, notably rhesus macaques, are widely
used as animal models in biomedical and immunological
research. In particular, both the Indian-origin and Chinese-
origin rhesus macaque models have contributed invaluable
information to the study of disease pathogenesis and novel
vaccine evaluation (Desrosiers 1990; Gardner and Luciw
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Persidsky and Fox 2007). However, these two distinct
geographic populations have displayed decidedly different
outcomes to infection despite their apparent physical
similarity (Joag et al. 1994; Otting et al. 2005, 2007),
perhaps attributive to genetic profile variations that affect
immune responses. Specifically, upon Simian immunodefi-
ciency virus (SIV) infection, Chinese rhesus macaques have
a more delayed and prolonged progression to AIDS as
compared to the animal populations of Indian origin (Ling
et al. 2002).
A number of studies have shown that several macaque
major histocompatibility complex (MHC; Mamu) class I
alleles, including Mamu-A*01 (Allen et al. 1998), Mamu-
B*17 (Mothe et al. 2002), and Mamu-B*01 (Loffredo et al.
2005) among others (Loffredo et al. 2004; Sette et al.
2005), are expressed with high frequency in Indian rhesus
macaque populations. Interbreeding of the Indian-origin
animals in the USA since 1978, when the exportation of
these animals from India was discontinued (Southwick and
Siddiqi 1988), has likely played a significant role in this
observation. The peptide-binding specificities for several of
these and other Indian rhesus MHC allelic forms have been
extensively characterized, leading to the identification of
specific alleles which influence disease progression (Mothe
et al. 2003;O ’Connor et al. 2003; Yant et al. 2006;
Loffredo et al. 2007) as well as the discovery of viral
evasion from cytotoxic T lymphocyte (CTL) responses
(Evans et al. 1999; Allen et al. 2000) in the SIV arena.
Indeed, Indian rhesus macaques are the model most utilized
in HIV- and AIDS-related research studies (Persidsky and
Fox 2007; Patterson and Carrion 2005; Gardner and Luciw
2008; Watkins et al. 2008). However, the increased demand
for these animals and, more importantly, the rapid progres-
sion to disease displayed after SIV infection of the Indian-
origin populations (Ling et al. 2002) have underscored the
advantages for developing alternative animal models.
Because of their relative accessibility, Chinese rhesus
macaques are becoming more widely employed as non-
human primate models in infectious disease research. They
are utilized for the evaluation of vaccines and the study of
immune responses in pathogen systems ranging from
Marburg virus, Ebola virus, and influenza virus to the
more well-studied SIV (Geisbert et al. 2007; Larsen et al.
2007; Carroll et al. 2008; Degenhardt et al. 2009; Ling et al.
2007, 2002). These animals, however, have not been
characterized at the MHC loci to the same extent as their
Indian counterparts. Studies to address this disparity have
revealed a surprisingly high degree of MHC polymorphism
(Otting et al. 2005, 2007, 2008; Karl et al. 2008; Ma et al.
2009; Wiseman et al. 2009; Ouyang et al. 2008). However,
it is largely non-overlapping with Indian-origin macaques
(Solomon et al. 2010). This polymorphism may be due to
the diverse geographic origins from which the animals have
been derived, comparable to human population distribution,
suggesting that Chinese rhesus macaques may represent
human leukocyte antigen (HLA) diversity more effectively
than those of Indian origin.
HLApolymorphismanditsfunctiontobindadiversearray
of antigenic peptides for CTL scrutiny have been well
documented, as has the existence of HLA supertypes, groups
of MHC molecules which share similar peptide-binding
specificities (Bjorkman and Parham 1990; Maryanski et al.
1986;P a r h a me ta l .1995; Sette and Sidney 1999;S i d n e ye t
al. 1995, a, b; Townsend et al. 2006). Previous studies have
demonstrated CTL repertoire overlaps between humans and
chimpanzees (Bertoni et al. 1998), as well as humans and
Indian rhesus macaques (Loffredo et al. 2009), suggesting
that HLA binding supertypes may extend to non-human
primates. Recently, the peptide-binding specificity associated
with the most frequent Chinese-origin allele, Mamu-
A1*02201, has been characterized and shown to be an
HLA-B7 supertype analog (Solomon et al. 2010), though it
is the only one to date. In order for Chinese-origin macaques
to become more valuable as animal models of infectious
disease research, continued investigation and characteriza-
tion of their MHC profile is necessary so cellular immunity
and immune correlates of protection can be more accurately
assessed.
We previously reported that 11 alleles were found in
multiple Chinese rhesus animals in different cohorts/
colonies, each with a cumulative frequency greater than or
equal to 5.6%. Combined, these alleles provide coverage
for approximately 68% of all Chinese rhesus animals
studied thus far and therefore represent a logical target for
further analysis and characterization (Solomon et al. 2010).
Accordingly, herein we sought to characterize Mamu-
A1*02601 (6.7%) and Mamu-B*08301 (5.8%), two of the
most frequently expressed Chinese-origin class I alleles. We
report the specific peptide-binding motifs associated with
these allelic forms and utilize their respective motifs to map
SIV-derived Mamu-A1*02601 and Mamu-B*08301 bind-
ing peptides.
Materials and methods
Creation of stable Mamu-A1*02601, Mamu-B*08301
transfectant cell lines
Stable MHC class I transfectants were produced in the
MHC class I deficient EBV-transformed B-lymphoblastoid
cell line 721.221. An expression construct was created for
Mamu-A1*02601 and Mamu-B*08301 by sub-cloning a
full-length allele transcript into separate pcDNA 3.1 vectors
(Invitrogen). These constructs were then used to transfect
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fector II transfection machine (Lonza AG, Walkersville,
MD, USA).
To produce secreted Mamu-A1*02601 molecules in the
context of endogenous ligand identification, α-chain
cDNAs of Mamu-A1*02601 were modified at the 3′ end
by PCR mutagenesis to delete codons 5–7 encoding the
transmembrane and cytoplasmic domains and to add a 30-
bp tail encoding the ten amino acid rat very low density
lipoprotein receptor (VLDLr), SVVSTDDDLA, for purifi-
cation purposes (Hickman et al. 2000). sMHC-VLDLr were
cloned into the mammalian expression vector pcDNA3.1
(Invitrogen); 721.221 cells were transfected with sMHC
Mamu-A*26TVLDLr by electroporation. After 48 h incu-
bation, cells were plated in 96-well plates (Falcon) in RPMI
1640 containing the antibiotic Geneticin. Transfectants
were tested for production of sMHC molecules by a
VLDLr-specific ELISA (Hawkins et al. 2008).
Mamu-A1*02601 endogenous ligand determination
Approximately 25 mg of Mamu-A*26TVLDLr molecules
from the 721.221 cell line were purified over an affinity
column composed of anti-VLDLr antibody (ATCC clone
CRL-2197) coupled to CNBr activated Sepharose 4B (GE
Healthcare, Piscataway, NJ, USA). sMHC molecules were
then eluted in 0.2 N acetic acid, brought up to 10% acetic
acid, and heated to 76°C for 10 min. Peptides were
separated from heavy and light chains by ultra-filtration in
a stirred cell with a 3-kDa molecular weight cutoff cellulose
membrane (Millipore, Bedford, MA, USA). The peptide
batch was flash frozen and lyophilized. The peptides were
then reconstituted in 10% acetic acid.
Following isolation, 10% of the peptide pool was
subjected to 14 rounds of N-terminal sequencing by Edman
degradation. A motif was generated by calculating the fold
increase of each amino acid over the prior round. A
hierarchy was then determined based on the amino acid
composition at each position (Falk et al. 1991).
Peptides were reverse-phase HPLC fractionated using a
Jupiter Proteo C12 column (Phenomenex, Torrance, CA,
USA) on a Paradigm MG4 system (Michrom Bioresources,
Auburn, CA, USA). A standard CH3CN gradient was
employed to generate approximately 40 peptide-containing
fractions. UVabsorption was monitored at 215 nm. Peptide
fractions were concentrated to dryness and reconstituted in
20 μl of nanospray buffer composed of 50% methanol,
50% H2O, and 0.5% acetic acid. Nano-electrospray
capillaries (Proxeon, Denmark) were loaded with 1 μlo f
each peptide fraction and infused at 1,100 V on a Q-Star
Elite quadrupole mass spectrometer with a time of flight
detector (Applied Biosystems, Foster City, CA, USA). Ion
maps were generated for each fraction in a mass range of
300–1,200 amu. Using independent data acquisition for
selection, ions (putative peptides) were fragmented by
tandem mass spectrometry (MS/MS). An amino acid
sequence was assigned using the publicly available, web-
based MASCOT (Matrix Science Ltd., London, UK) and/or
de novo sequencing.
Positional scanning combinatorial library and peptide
synthesis
Positional scanning combinatorial libraries (PSCL) were
synthesized as previously described (Pinilla et al. 1999). In
the PSCL, each pool in the library contains randomized 9-
mer peptides with one fixed residue at a single position.
With each of the 20 naturally occurring residues represented
at each position along a 9-mer backbone, the entire library
consisted of 180 peptide mixtures.
Peptides utilized in screening studies were purchased as
crude or purified material from Mimotopes (Minneapolis,
MN, USA/Clayton, Victoria, Australia), Pepscan Systems B.
V. (Lelystad, The Netherlands), A&A Labs (San Diego, CA,
USA), Genescript Corporation (Piscataway, NJ, USA), or the
Biotechnology Center at the University of Wisconsin—
Madison (Madison, WI, USA). Peptides synthesized for use
as radiolabeled ligands were synthesized by A&A Labs and
purified to >95% homogeneity by reverse-phase HPLC.
Peptide purity was determined with analytical reverse-phase
HPLC and amino acid analysis, sequencing, and/or mass
spectrometry. Peptides were radiolabeled utilizing the chlora-
mine T method (Sidney et al. 2001b). Lyophilized peptides
were re-suspended at 4–20 mg/ml in 100% DMSO, then
diluted to required concentrations in PBS+0.05% (v/v)
nonidet P40 (Fluka Biochemika, Buchs, Switzerland).
SIV peptide sequences were derived from the SIVmac239
sequence, GenBank accession M33262 (Kestler et al. 1990).
MHC purification for peptide-binding assays
HLA and Mamu class I MHC purification was performed
by affinity chromatography using the W6/32 and/or B123.2
class I antibodies, as previously described (Sidney et al.
2001b, 2005;L o f f r e d oe ta l .2009). Protein purity,
concentration, and depletion efficiency steps were moni-
tored by SDS-PAGE.
Quantitative assays for peptide binding to detergent
solubilized MHC class I molecules were based on the
inhibition of binding of a high-affinity radiolabeled stan-
dard probe peptide and performed as detailed in prior
studies (Loffredo et al. 2004; Schneidewind et al. 2008;
Sidney et al. 2001b, 2005). Peptides were tested at six
different concentrations covering a 100,000-fold dose range
in three or more independent assays. Control wells to
measure non-specific (background) binding were also
Immunogenetics (2011) 63:275–290 277included. In each experiment, a titration of the unlabeled
version of the radiolabeled probe was also tested as a
positive control for inhibition.
The radiolabeled peptide utilized for the Mamu-A1*02601
assay was 3317.02 (sequence YLPTQQDVL), representing a
sequence identified by Edman degradation and mass spec-
trometry analysis (described above). For Mamu-B*08301
assays, peptide 3317.04 (KSINKVYGK, an R9->K analog of
Vaccinia B13R, an HLA-A3 supertype degenerate binder)
was used. For each peptide, the concentration of peptide
yielding 50% inhibition of the binding of the radiolabeled
probe peptide (IC50) was calculated. Under the conditions
used, where [radiolabeled probe] < [MHC] and IC50≥
[MHC], the measured IC50 values are reasonable approx-
imations of the true Kd values (Gulukota et al. 1997;S e t t ee t
al. 1994a;C h e n ga n dP r u s o f f1973).
Bioinformatic analysis
We performed analysis of the PSCL data as described
previously (Sidney et al. 2008). Briefly, IC50 (nanomolars)
values for each residue/position mixture were standardized
as a ratio to the geometric mean IC50 (nanomolars) value of
the entire set of 180 mixtures and further normalized to the
average of libraries tested at each position. To identify
predicted binders, all possible 9-mer peptides in SIV-
mac239 sequences were scored using the matrix values
derived from the PSCL analyses of Mamu-A1*02601 and
Mamu-B*08301. The final score for each peptide repre-
sents the product of the corresponding matrix values for
each peptide residue–position pair. Peptides scoring among
the top 3.0% (n=100) were selected for binding analysis.
Phylogenetic analysis
We assembled representative MHC class I sequences from
humans, Chinese, and Indian rhesus macaques. Sequences
were normalized to 1,068 nucleotides in length and aligned
using the ClustalX program (Thompson et al. 2002). A
phylogenetic tree was built with the neighbor-joining method
(Saitou and Nei 1987) using the Tamura three-parameter
distance model (Tamura 1992). One thousand bootstrap
samples were analyzed to ensure reliable clustering.
Results
Determination of natural Mamu-A1*02601 ligands
Previous studies have demonstrated that the elution and
characterization of naturally bound ligands is an effective
method for determining the peptide-binding specificity of
class I MHC molecules (Hickman-Miller et al. 2005; Kubo
et al. 1994). Accordingly, an initial evaluation of the
peptide-binding specificity of soluble Mamu-A1*02601
was determined by sequencing 30 different endogenously
loaded Mamu-A1*02601 peptide ligands representing 14
different peptide fractions (Table 1). The majority of
ligands (80%; 24 out of 30) were nine residues in length,
with only four and two ligands identified of ten and 11
residues, respectively. This observation suggests that 9-
mers represent the preferred size for peptide ligands bound
to Mamu-A1*02601.
Next, peptides were aligned and at each position, the
frequency of each residue was tabulated (Supplemental
Table 1, online resource). At position 2, leucine (L) was
found in 15 of the 30 ligands, and other aliphatic residues
valine (V) and isoleucine (I) were present in ten and three
ligands, respectively. The amide residue glutamine (Q) was
found in 15 peptides at position 6, and related residues
Table 1 Endogenous Mamu-A1*02601 ligands identified by MS/MS
sequencing analysis
Fraction Ion Length Peptide sequence
53 457.7 9 ALGPTNKTL
53 508.7 9 RLPTSQSDL
53 536.2 9 LVADEQQRL
55 520.7 9 SVTLHQDQL
55 538.7 9 YVPEAQTRL
57 507.2 9 GLVVKQEQL
57 552.2 9 WVGESERQL
59 514.7 9 VVSVPQRIM
59 534.3 9 RVGERQPLL
61 508.2 9 VLIKTAEEL
61 515.7 9 SLEIGENRL
61 538.7 9 YLPTQQDVL
61 568.3 10 YAAISQVDRL
63 526.7 9 RVHIGQVIM
63 612.3 10 SLPNFKQNEF
65 541.2 9 LINITEHEL
65 554.2 9 FLIRESETL
67 488.7 9 SLPHPEALL
67 552.7 9 AVRIEQEFL
69 478.7 9 ASLLIQQAL
69 535.8 9 IVTILQDRL
71 485.7 9 GLDIPEVDL
71 490.2 9 HINIGALEL
71 505.2 9 HVSLVQLTL
71 590.8 9 FLRFQEEVL
73 541.8 10 ALPDIKVLTL
73 649.8 11 RLPTDTLQELL
77 564.3 10 AISILQQLEI
77 592.3 11 ALPSDLLENVL
79 516.7 9 ALPEIFTEL
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ligands. At the C terminus, L was dominant (26 out of 30
peptides). The related aliphatic residues methionine (M)
and I were also present at the C terminus. This information
presents a preliminary motif with positions 2 and 6 and the
C terminus, tentatively assigned as the main anchor
positions based on ≥50% residue frequency.
Establishment of peptide-binding assays
for Mamu-A1*02601 and Mamu-B*08301
To functionally characterize Mamu-A1*02601 further,
MHC class I molecules expressed in single cell trans-
fectants of 721.221 lines were purified by affinity chroma-
tography. To establish a Mamu-A1*02601 binding assay,
we took advantage of the natural ligand sequence informa-
tion previously described. Accordingly, Mamu-A1*02601
natural ligands containing tyrosine (Y), an amino acid to
which gamma-radioactive isotopes of iodine can attach,
were synthesized and their capacity to bind purified MHC
investigated. We found that the ligand YLPTQQDVL
(peptide ID 3317.02) was associated with prominent
binding to Mamu-A1*02601 (Fig. 1a). Significant binding
was observed with as little as 700 pM of purified Mamu-
A1*02601. The binding of YLPTQQDVL was also
selective, since no significant binding was observed to
purified Mamu-B*08301 molecules.
Endogenous ligands or defined epitopes for the Mamu-
B*08301 molecule have not been reported. However,
previous studies demonstrated that HLA supertype ligands
also bind to MHC molecules expressed in other species,
such as chimpanzees (Pan troglodytes), mice (Mus muscu-
lus; McKinney et al. 2000; Sette et al. 2005; Sidney et al.
2006), and, recently, Chinese rhesus macaques (Solomon et
al. 2010), where the most frequent allele Mamu-A1*02201
was shown to be an analog of the HLA-B7 supertype.
Hierarchical clustering analysis performed by our group
(data not shown) predicted that Mamu-B*08301 might be
associated with an HLA-A3 supertypic peptide-binding
specificity. Experiments examining direct binding for a
panel of HLA-A3-supertype peptides to Mamu-B*08301
were performed. An analog of a Vaccinia-derived HLA-A3
supertype ligand (KSINKVYGK, peptide 3317.04) bound
Mamu-B*08301 with significant counts and showed spec-
ificity, displaying negligible binding to Mamu-A1*02601
(Fig. 1b).
Furthermore, the binding for both alleles was specific at
the level of inhibition by unlabeled ligands. Mamu-
A1*02601 binding to the radiolabeled YLPTQQDVL
ligand could be inhibited by an excess of unlabeled
3317.02 peptide with an IC50 value of approximately
0.2 nM. Mamu-B*08301 binding to the radiolabeled
KSINKVYGK ligand could be inhibited by an excess of
unlabeled 3317.04 with an IC50 value of approximately
0
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Fig. 1 The development of the
Mamu-A1*02601 and Mamu-
B*08301 MHC–peptide-binding
assays. The endogenous Mamu-
A1*02601 ligand
YLPTQQDVL (peptide
3317.02) and HLA-A3 super-
type ligand Vaccinia B13R ana-
log KSINKVYGK (peptide
3317.04) were utilized as radio-
labeled probes in direct binding
dose titration experiments to
ascertain binding potential to
purified Mamu MHC molecules.
a The radiolabeled ligand
YLPTQQDVL binds Mamu-
A1*02601 (solid circle), but not
B*08301 (open triangle). b The
radiolabeled ligand KSINK-
VYGK binds Mamu-B*08301
(solid triangle), but not
A1*02601 (open circle). c Inhi-
bition of radiolabeled ligand
binding to Mamu-A1*02601
and Mamu-B*08301 by excess
unlabeled 3317.02 and 3317.04
ligands in dose titration binding
experiments demonstrated spec-
ificity of binding
Immunogenetics (2011) 63:275–290 2792.0 nM (Fig. 1c). In conclusion, these results demonstrate
that the binding assays are specific for the purified MHC
molecule and thus enable detailed investigation of the
peptide-binding specificity for both Mamu-A1*02601 and
Mamu-B*08301.
Definition of Mamu-A1*02601 peptide-binding motif
Building upon our mass spectrometric analysis of Mamu-
A1*02601 eluted ligands, we next tested the capacity of 9-
mer PSCL to bind purified Mamu-A1*02601 MHC to
further define the peptide-binding motif (Fig. 2). The
binding capacity relative to the geometric mean for the
entire PSCL (IC50=2,438 nM) was determined for each
positional/residue mixture and further normalized to the
average of libraries tested at each position, as previously
described (Sidney et al. 2008). For this analysis, we defined
preferred residues as those that displayed 20-fold higher
binding capacity than the position average and defined
tolerated residues as those that displayed 4-fold higher
binding. We defined a main binding anchor as a position in
which at least half of the residues (≥10) are associated with
binding capacity either 4-fold higher (in blue in Fig. 2)o r
lower (orange) than the position average. Furthermore,
secondary anchors are defined as those positions associated
with at least five residues (25%), but less than ten,
employing the same binding criteria.
Accordingly, position 2 and the C terminus are the main
anchor positions. At position 2, L, M, and V were
overwhelmingly preferred above all other residues, while I
and N were well tolerated. At the C terminus, residues L, I,
and M were preferred and alanine (A), phenylalanine (F),
glycine (G), and V were tolerated. Using the aforemen-
tioned criteria, position 1 is a secondary anchor with
preferences for F and Y. Position 6, although failing to
meet our secondary anchor criteria by one amino acid, has a
very strong preference for Q, as displayed by a PSCL ratio
of 41. These data are in overall agreement with the data
observed with the natural ligands and were used to derive a
Mamu-A1*02601 motif (Fig. 3). The observation that M
was not identified in the natural ligand analysis, an exercise
not intended to be comprehensive, but shown to be a
preferred p2 anchor residue by PSCL, could in part be
attributed to the residue’s low observed frequency in nature.
The fact that both L and M contribute comparable binding
potential at an anchor position stems from their shared
chemical similarity as hydrophobic, aliphatic residues.
Identification of Mamu-A1*02601 binding SIV-derived
peptides
Next, we determined if the PSCL-based motifs could be
used to identify Mamu-A1*02601 binding peptides. With
Chinese rhesus macaques becoming an increasingly utilized
animal model in SIV pathogenesis studies, we targeted the
SIV proteome for these experiments (Joag et al. 1994; Ling
et al. 2002; Trichel et al. 2002; Burdo et al. 2005;
Monceaux et al. 2007; Degenhardt et al. 2009). The PSCL
Position
Residue 123456789
A 3.6 1.1 2.2 1.0 1.5 8.1 1.1 6.0 8.0
C 3.3 0.49 0.94 0.33 1.3 0.30 2.0 0.56 0.33
D 0.051 0.13 0.48 0.28 0.19 1.2 1.3 0.82 0.23
E 0.17 0.066 0.077 0.081 0.34 0.32 0.022 0.13 0.17
F 6.9 1.5 0.98 1.8 1.8 0.44 2.6 1.4 7.5
G 2.6 0.23 2.1 0.41 1.2 0.34 1.4 0.77 4.6
H 1.2 0.17 0.26 0.96 0.42 1.9 0.46 0.58 0.16
I 0.75 17 1.7 3.4 1.9 0.53 2.9 5.9 31
K 2.8 0.19 1.3 0.39 0.47 0.17 0.22 0.32 0.17
L 1.5 25 0.77 3.7 0.72 0.45 1.4 1.2 110
M 3.2 26 1.0 2.2 1.2 3.1 2.5 0.61 29
N 0.63 4.5 1.7 0.90 0.57 12 0.85 0.30 0.26
P 0.090 0.41 0.85 1.5 1.9 0.37 1.3 1.3 0.098
Q 0.43 2.0 1.1 1.1 1.3 41 2.2 2.2 0.20
R 2.8 0.28 0.83 1.2 1.2 1.1 0.31 1.1 0.098
S 0.39 0.65 2.0 0.91 0.99 2.2 0.97 1.0 0.17
T 0.22 0.89 2.5 1.1 0.78 1.3 1.8 2.4 0.79
V 0.81 20 2.0 3.2 2.4 0.47 1.2 3.8 5.3
W 2.1 0.32 1.3 2.1 2.6 0.33 0.71 0.34 0.31
Y 4.4 0.46 0.91 1.5 1.3 0.37 3.7 1.1 1.0
Fig. 2 The relative influence of
amino acids at each position on
the binding to Mamu-
A1*02601. The 9-mer positional
scanning combinatorial library
was tested for binding to Mamu-
A1*02601. Values represent the
ratio of the IC50 (nanomolars) of
each pool at a given position
relative to the geometric mean
for the entire library (2,438 nM)
and further normalized to the
average of libraries tested at
each position. Ratios of 0.25
or less are highlighted in
orange; >4 are in blue
280 Immunogenetics (2011) 63:275–290matrix was used to score all 9-mer peptides in the
SIVmac239 proteome. Peptides scoring in the upper 3.0%
range (n=100) were tested for binding capacity (Supple-
mental Table 2, online resource). Additionally, a set of 35
control peptides, ranging from 3.1% to 70% in rank (five
peptides randomly selected within each 10% demarcation),
was also tested.
Previous SIV epitope and in vivo T cell recognition
studies have established 500 nM as an appropriate peptide-
binding threshold of immunogenicity (Sette et al. 1994a, b;
van der Most et al. 1998; Vitiello et al. 1996; Allen et al.
2001; Loffredo et al. 2004, 2005; Mothe et al. 2002; Sette
et al. 2005). In total, 45 of the 100 “top 3% score” peptides
bound Mamu-A1*02601 with an affinity of 500 nM or less
(Table 2). Of those, 21 were high-affinity binders, possess-
ing an IC50≤50 nM. By contrast, none of the 35 lower-
scoring control peptides resulted in similar affinities.
Furthermore, 25 of the 45 binders with affinity ≤500 nM
(56%) scored in the top 1% of predicted peptides, as well as
76% (16 of 21) of high-affinity binders.
Mamu-A1*02601 and the HLA-A2 MHC molecules share
overlapping binding repertoires
The results described above define a Mamu-A1*02601
motif that appeared to match the motif associated with
HLA-A2 supertype alleles, which is characterized by a
preference for aliphatic and hydrophobic residues at
position 2 and at the C terminus (Sidney et al. 2001a).
Based on this observation, we predicted that cross-
reactivity between these human and macaque molecules
may exist (Dzuris et al. 2000). To investigate this
hypothesis, we tested the 45 top SIV-derived binders
(IC50≤500 nM) described above for binding to HLA-A2
supertype molecules (HLA-A*0201, HLA-A*0202, HLA-
A*0203, HLA-A*0206, and HLA-A*6802). Twenty-seven
of these 45 Mamu-A1*02601 binders (60%) bound at least
one molecule of the HLA-A2 superfamily with an IC50≤
500 nM (Fig. 4), with 18 (40%) being promiscuous binders,
binding three or more HLA-A2 alleles. One peptide,
FLIRQLIRL (Env.771), bound all five HLA-A2 supertype
molecules examined.
HLA-A*0202 displayed the highest degree of cross-
reactivity with Mamu-A1*02601. Of the 27 Mamu-
A1*02601 binders that bound an A2-like allele, 23 (85%)
bound HLA-A*0202. Additionally, 17 of the 18 promiscu-
ous binders (94%) bound HLA-A*0202. HLA-A*0201 and
HLA-A*0203 were also highly cross-reactive, as both
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Fig. 3 Map of the Mamu-A1*02601 motif. Pictorial summary
representation of the Mamu-A1*02601 PSCL matrix, indicating
residues contributing positive or negative binding potential by
position. The total number of residues affecting binding by position
is summed, with a double-digit score indicating primary anchor
position. Preferred residues at anchor positions, defined as residues
showing a 20-fold increase in binding capacity versus the position
average, are highlighted in larger font. Positions 2 and the C terminus
are identified as main anchor positions
Table 2 The efficiency of PSCL matrices in predicting Mamu-
A1*02601 binders
Peptides tested
a Mamu-A1*02601 binding affinity
(IC50, nM)
Prediction rank n <50 50–500 >500
Top 1.0% 33 16 9 l8
1.1–2.0% 33 3 12 18
2.1–3.0% 34 2 3 29
3.1–70%
b 35 0 0 35
Total 135 21 24 90
aAll possible 9-mer peptides in the SIVmac239 proteome were scored
using the matrix values derived from the Mamu-A1*02601 PSCL analysis.
The final score for each peptide represents the product of the corresponding
matrix values for each peptide residue–position pair. Peptides scoring
a m o n gt h et o p3 . 0 %( n=100) were selected for characterization
bA set of 35 control peptides scoring in the 3.1–70% range, five
peptides randomly selected within each 10% demarcation, was also
examined
Immunogenetics (2011) 63:275–290 281alleles bound 18 Mamu-A1*02601 binders (67%); 16 of
these cross-reactive peptides were shared between the two
alleles.
Interestingly, the amino acid present at position 6 greatly
influences cross-reactivity. More specifically, while Q at
position 6 is strongly preferred for Mamu-A1*02601
binding, peptides possessing Q at position 6 are less likely
to cross-react with HLA-A2 supertype molecules. Indeed,
only 14% (three out of 21) of Mamu-A1*02601 binders
with Q at position 6 were promiscuous HLA-A2 supertype
Sequence Source Mamu-
A1*02601
HLA-
A*0201
HLA-
A*0202
HLA-
A*0203
HLA-
A*0206
HLA-
A*6802
LIRILQRAL Vpr.61 0.00091 3748 362 492 1225 3373
YLCLIQKAL Vpx.71 0.042 57 29 167 4345  --
MLTACQGVG Gag.347 0.77 10,267 985 927  -- 13,395
FLIRQLIRL Env.771 0.83 1.2 0.64 1.1 2.2 489
IIVDSQYVM Pol.702 1.0 832 215 5189 1136 6002
IVQQQQQLL Env.561 1.0 4578 977 8337 9921 9547
GIVQQQQQL Env.560 1.7 5818 871 8547  --  --
TVPWPNASL Env.620 2.7 821 222 1878 6135 102
LVQYMDDIL Pol.388 9.7 253 72 173 7831 12,322
FLATAGSAM Env.535 12 161 8.5 7.7 1467 5558
RVVLQSKEL Pol.408 13 6239 1457 2475 1300 2143
AMGAASLTL Env.542 15 174 59 56 7521  --
WIKYIQYGV Env.687 16 230 20 1.7 944 1.1
KNWMTQTLL Gag.315 17 1979 4494 11,287 7753 11,442
KIGKEAIVI Pol.581 21 16,219 1802 2651  --  --
SPAIFQYTM Pol.364 26  -- 3189  --  -- 1087
LLTALGMSL Pol.198 28 19 7.9 37 38 10,106
CVGDHQAAM Gag.192 38  -- 2691 4596  --  --
RMYNPTNIL Gag.276 41 418 78 101 6560 381
GPKLKQWPL Pol.226 42  -- 4575 12,855  -- 2009
CLIQKALFM Vpx.73 45 788 1776 2353 7103  --
HVVWAANEL Gag.33 72 10,997 1510 11,074 1031 19
RIVARQIVD Pol.797 94 5910 4718 6544 10,467 2714
RILQRALFM Vpr.63 104  -- 6027 11,322  -- 9890
FLGFLATAG Env.532 106 309 200 23 3095  --
GVRLLAHVI Pol.571 107  -- 10,038 4844  --  --
NQLLIAILL Env.6 117 5600 4955 4479 185 7638
YRRWIQLGL Gag.263 119 14,959 5165 2224  --  --
KILSVLAPL Gag.59 123 3.0 23 47 2.2 3183
LLSRVYQIL Env.790 135 35 2.5 28 4578 4921
WMYRQQNPI Gag.249 138 169 24 72 893 996
WLSTYAVRI Vif.81 170 108 7.0 108 1097 14,675
VYQILQPIL Env.794 184 9223 128 410 9321  --
RLIRGKMTL Pol.489 217 151 72 83 908  --
VIYIVQMLA Env.707 243 1438 2360 1176 293 4533
YNPQSQGVV Pol.910 251  -- 3863 2176  --  --
KIIIVAVHV Pol.838 340 3883 3655 1542 1594 7353
GNYPVQQIG Gag.133 343 4992 329 2251 13,973 14,992
IVIYIVQML Env.706 354 382 644 1010 258 219
GFAAPQFSL Pol.106 372 11,843 548 5309  -- 15,237
MAQVHQGLM Gag.449 431 18,523 4361 3975  -- 7121
KLSPLCITM Env.103 440 77 85 1158 85  --
QPAPQQGQL Gag.220 452 4669 497 979  --  --
ILQRLSATL Env.801 475 1.4 0.22 6.1 1381 6833
GLVFHSQPI Env.327 491 234 9.7 34 4758 5130
IC50 nM to puriﬁed molecules
Fig. 4 Mamu-A1*02601 bind-
ers tested against HLA-A2
supertype alleles. SIVmac239-
derived, Mamu-A1*02601
predicted peptides which had
an IC50 e500nM n ¼ 45 ðÞ were
tested for binding capacity
to HLA-A2 supertype mole-
cules. Affinities highlighted
in blue possess an IC50<50 nM.
Those affinities in the 50–
500 nM range are highlighted
in green. Dashes indicate
binding affinity >20,000 nM
282 Immunogenetics (2011) 63:275–290binders, while 63% (15 out of 24) of Mamu-A1*02601
binders that did not have Q at p6 bound three or more
HLA-A2 supertype molecules.
Definition of Mamu-B*08301 peptide-binding motif
As was performed for Mamu-A1*02601, we tested the
capacity of 9-mer PSCLs to bind Mamu-B*08301 mole-
cules (Fig. 5). The binding affinity relative to the geometric
mean for the entire PSCL (518 nM) was determined. Using
the criteria outlined above, the C terminus was identified as
the dominant anchor position, with the basic positively
charged residues lysine (K) and arginine (R) being
overwhelmingly preferred and residues F, L, and Y being
tolerated. Unlike Mamu-A1*02601, a second main anchor
position was not identified for Mamu-B*08301. Instead,
position 2 was defined as a secondary anchor. In this
position, the most preferred residues were N and serine (S),
while threonine (T) was tolerated. These data were
subsequently used to derive a Mamu-B*08301 motif
(Fig. 6).
Identification of Mamu-B*08301 binding SIV-derived
peptides
Repeating the exercise performed for Mamu-A1*02601, all
9-mer peptides in the SIVmac239 proteome were scored
using the Mamu-B*08301 PSCL matrix. Peptides scoring
in the upper 3.0% range (n=100) were tested for binding
capacity (Supplemental Table 3, online resource), and a set
of control peptides was included.
In total, 64 of the 100 “top 3% score” peptides bound
Mamu-B*08301 with an affinity of 500 nM or less, and of
those, 32 were high-affinity binders (Table 3). Furthermore,
30 of the 64 binders with affinity ≤500 nM (47%) scored in
the top 1% of predicted peptides, as well as 72% (23 of 32)
of high-affinity binders. By contrast, none of the 35 control
peptides had an IC50<1,900 nM.
Mamu-B*08301 and the HLA-A3 MHC molecules share
overlapping binding repertoires
The results presented for Mamu-B*08301 depict a motif
that closely resembles the one associated with HLA-A3
supertype alleles, which is characterized by a preference for
basic residues at the C terminus and small and aliphatic
residues at position 2 (Sidney et al. 1996a). Revisiting our
hypothesis of the potential for cross-reactivity between
human and macaque alleles, we tested the 64 top SIV-
derived binders (IC50≤500 nM) for binding to HLA-A3
supertype molecules (HLA-A*0301, HLA-A*1101, HLA-
A*3101, HLA-A*3301, and HLA-A*6801). Fifty-two of
the 64 Mamu-B*08301 binders (81%) bound at least one
molecule of the HLA-A3 superfamily with an IC50≤
500 nM (Fig. 7).
HLA-A*3101 displayed the highest degree of cross-
reactivity with Mamu-B*08301. Of the 52 Mamu-B*08301
binders that bound an A3-like allele, 39 (75%) bound HLA-
Position
Residue 123456789
A 2.4 2.4 1.1 0.71 1.5 0.77 0.61 2.2 2.3
C 3.1 0.48 1.0 0.73 2.0 0.98 1.8 0.62 0.28
D 0.63 0.50 1.7 1.2 0.98 0.67 2.0 0.20 0.24
E 0.14 0.15 0.42 0.23 0.95 1.2 0.77 0.21 0.18
F 2.0 0.97 8.5 1.6 4.4 6.1 1.6 7.8 8.6
G 3.2 2.0 0.65 1.5 0.78 1.0 1.1 1.4 0.28
H 0.57 0.18 0.71 0.43 0.63 1.7 0.70 1.2 0.82
I 0.50 0.68 1.6 0.22 1.3 1.4 3.1 0.64 0.83
K 0.96 0.79 0.38 0.77 0.21 0.32 0.18 0.89 154
L 0.45 0.42 1.5 0.82 0.55 0.71 2.1 1.6 5.1
M 4.5 0.79 5.5 1.4 0.89 1.0 1.7 0.71 2.5
N 1.2 70 1.6 2.5 0.29 1.8 0.58 0.82 0.28
P 0.084 1.1 0.14 1.1 0.62 0.90 1.0 1.4 0.058
Q 2.8 0.92 1.1 0.91 3.1 1.0 0.62 1.7 0.062
R 2.1 0.21 0.19 0.64 0.26 0.48 0.17 1.2 126
S 2.0 22 1.2 5.8 1.3 0.76 1.3 0.66 0.33
T 0.70 6.8 0.74 0.67 0.56 0.56 0.98 0.95 0.16
V 0.31 1.3 0.86 0.93 0.77 1.0 0.74 0.68 1.3
W 1.4 0.19 0.72 1.8 5.7 1.5 1.7 0.57 0.31
Y 1.2 0.34 2.6 3.0 2.6 0.90 2.2 3.3 4.2
Fig. 5 The relative influence of
amino acids at each position on
the binding to Mamu-B*08301.
The 9-mer positional scanning
combinatorial library was tested
for binding to Mamu-B*08301.
Values represent the ratio of the
IC50 (nanomolars) of each pool
at a given position relative to the
geometric mean for the entire
library (518 nM) and further
normalized to the average of
libraries tested at each position.
Ratios of 0.25 or less are high-
lighted in orange; >4 are in blue
Immunogenetics (2011) 63:275–290 283A*3101. HLA-A*0301 and HLA-A*6801 also displayed
good cross-reactivity, as both alleles bound at least 26
Mamu-B*08301 binders. Additionally, 41% of Mamu-
B*08301 binders (26 out of 64) were promiscuous HLA-
A3 supertype binders, a percentage that is comparable to
that seen between Mamu-A1*02601 and HLA-A2 (40%).
Evolutionary origin of Chinese rhesus macaque HLA-A2
and HLA-A3 functional analogy
The two common Chinese rhesus class I alleles described
above are associated with HLA-A2 and HLA-A3 supertype
specificities, which have not been detected in Indian rhesus
macaques, although functional analysis of many of the most
common alleles expressed in Indian-origin animals has been
performed. To investigate the evolutionary origin of the
functional analogy between the HLA and Chinese rhesus
macaque MHC class I alleles in this study, we built a
phylogenetic tree using representative MHC allele sequences.
For humans, we included one HLA allele (HLA-
A*01010101, HLA-A*02010101, HLA-A*03010101, HLA-
A*24020101, HLA-B*070201, HLA-B*080101, HLA-
B*270202, HLA-B*44020101, HLA-B*580101, and HLA-
B*15010101) from each of the known supertypes (A1, A2,
A3, A24, B7, B8, B27, B44, B58, and B62 respectively)
with an additional four HLA-B7 supertype alleles (HLA-
B*35010101, HLA-B*510101, HLA-B*530101, and HLA-
B*5401) and the four additional HLA-A2 supertype alleles
(HLA-A*0202, HLA-A*020301, HLA-A*020601, and HLA-
A*68020101) and HLA-A3 supertype alleles (HLA-
A*110101, HLA-A*310102, HLA-A*330101,a n dHLA-
A*680101) that were used in this study. For Indian rhesus
macaques, we selected 14 sequences represented among the
most common specificities (Boyson et al. 1996; Kaizu et al.
2007; Knapp et al. 1997; Loffredo et al. 2007; Voss and
Letvin 1996). Similarly, the 14 Chinese rhesus macaque
sequences included in the analysis were selected from the
most frequent alleles (Solomon et al. 2010).
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Fig. 6 Map of the Mamu-B*08301 motif. Pictorial summary
representation of the Mamu-B*08301 PSCL matrix, indicating
residues contributing positive or negative binding potential by
position. The total number of residues affecting binding by position
is summed, with a double-digit score indicating primary anchor
position. Preferred residues at anchor positions, defined as residues
showing a 20-fold increase in binding capacity versus the position
average, are highlighted in larger font. The C terminus position is
identified as the sole main anchor position
Table 3 The efficiency of PSCL matrices in predicting Mamu-B*08301 binders
Peptides tested
a Mamu-B*08301 binding affinity (IC50, nM)
Prediction rank n <50 50–500 >500
Top 1.0% 33 23 7 3
1.1–2.0% 33 4 13 16
2.1–3.0% 34 5 12 17
3.1–70%
b 35 0 0 35
Total 135 32 32 71
aAll possible 9-mer peptides in the SIVmac239 proteome were scored using the matrix values derived from the Mamu-B*08301 PSCL analysis.
The final score for each peptide represents the product of the corresponding matrix values for each peptide residue–position pair. Peptides scoring
among the top 3.0% (n=100) were selected for characterization
bA set of 35 control peptides scoring in the 3.1–70% range, five peptides randomly selected within each 10% demarcation, was also examined
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B*08301
HLA-
A*0301
HLA-
A*1101
HLA-
A*3101
HLA-
A*3301
HLA-
A*6801
TNYSGFMPK Env.246 0.10 37 16 111 1.4 9.0
MSLNFPIAK Pol.204 0.15 2.3 2.7 41 114 21
ANFASQEVK Pol.886 0.18 1287 158 2467 10,380 188
QSYVDRFYK Gag.295 0.23 15 5.0 11 77 8.2
YNTPTFAIK Pol.264 0.38 442 1808 96 336 45
SNVKELVFK Pol.784 0.41 2185 976 390 698 552
KNSKFKNFR Pol.983 0.46 18,379  -- 26 872 2904
ASNKPISNR Tat.96 0.51 2.2 11 0.99 17 65
RNYVPCHIR Env.427 0.58 2131 4257 1.3 52 586
ANTSSASNK Tat.91 0.93 854 1306 2746 1959 2363
MSPSYVKYR Vpx.62 1.4 139 194 29 58 2.5
GNNTGNESR Env.197 1.8 287 253 76 473 1024
LNAWGCAFR Env.606 1.8 369 422 45 78 15
SNCRTLLSR Env.785 1.9 938  -- 24 35 321
SSLSCEGQK Nef.51 2.0 242 127 1091 398 614
RQTALFLLK Pol.862 2.2 3.4 16 12 7637 454
KTGMLEMWK Pol.19 2.2 6.3 11 150 12,587 1365
RNSVLSGKK Gag.4 2.2 522 2911 58 1573 1851
SGFMPKCSK Env.249 2.4 250 482 408 4538 124
RNTANQKPK Env.414 3.1 3210 13,062 2567 4354 1857
RSRPSGDLR Nef.9 6.1 316 8864 2.1 584 722
YNLTMKCRR Env.305 8.3 3872  -- 142 66 802
SQDNQWSYK Pol.540 8.3 144 27 87 243 542
NTPTFAIKK Pol.265 8.9 113 175 2938 2488 2.5
GANFPGLAK Vif.200 16 22 14 448 2966 373
CNKQSKEGK Pol.653 19 17,118  -- 151 4080 2406
FKNFRVYYR Pol.987 21 9899 14,370 6.0 6.3 121
AIDMSHFIK Nef.116 21 89 15 3277 19,014 841
RTYIYWHGR Env.285 24 4.0 27 0.89 66 46
LVFKFGLPR Pol.789 36 18 57 1.0 15 2.1
FNGTRAENR Env.277 39  --  -- 848 328 1860
QNSRGDKQR Vif.184 42  -- 13,654 565 14,746 1612
ACYNTCYCK Tat.49 53 225 2656 1437 8729 1756
VNNAEPGKR Pol.343 56 1355  -- 203 17,345 2822
SAEVAELYR Env.483 64 12,730 781 1038 1765 4.3
KNTHTNGVR Pol.565 65 1633 17,663 729 7140 7162
QRALFMHFR Vpr.66 81 2373 11,314 19 207 24
YRYLCLIQK Vpx.69 82 1355 2049 940 786 1828
KVCYVPHFK Vif.38 102 11 205 3.0 2126 128
RGDKQRGGK Vif.187 108 115 17,868 3573  --  --
MAVHCMNFK Pol.945 111 59 194 13 1876 141
MGYELWPTK Pol.438 124 1541 823 2842 874 7999
QKALFMHCK Vpx.76 125 308 1194 799 3183 1454
KALFMHCKK Vpx.77 125 70 698 68 10,686 3861
PSLQYLALK Vif.146 138 1165 1425 2210 6485 1589
GNSSWPWQI Env.758 139 2831 3214 443 6931 8674
APQFSLWRR Pol.109 164 3448 1108 48 135 303
QILQPILQR Env.796 168 683 1530 148 147 114
GFINTKEYK Pol.161 175 936 2576 336 820 2634
HCQFCFLKK Tat.62 184 68 1087 431  -- 1848
ETDRWGLTK Env.117 206 142 545 417  -- 9697
CNDTNYSGF Env.243 223 8638 8485 3587 7655 325
TTSTTASAK Env.133 247 23 141 12,497 12,075 11
QAWCWFGGK Env.341 295 2611 2276 1883 18,923 1179
GPCYGQMPR Pol.29 303 1113 8290 401 5706 370
KGEGAVILK Pol.1011 311 1206 1499 2366  -- 5242
SGLSEEEVR Nef.237 382 16,769  -- 5232 14,259 3413
ANFPGLAKV Vif.201 407 6314  -- 1019 6336  --
RGPSCGSAK Pol.71 410 313 1419 3544  -- 761
CKFNMTGLK Env.168 427 812 10,722 739 2258 5351
GKMDHVMAK Gag.418 428 593 1202 44 279 275
QGMSPSYVK Vpx.60 476 406 857 92 2126 8334
VTFMWTNCR Env.388 482 761 4570 30 1383 1206
GIGGFINTK Pol.158 484 344 179 5659 19,497 3201
IC50 nM to puriﬁed molecules Fig. 7 Mamu-B*08301 binders
tested against HLA-A3 super-
type alleles. SIVmac239-
derived, Mamu-B*08301
predicted peptides which had
an IC50 e500nM n ¼ 64 ðÞ were
tested for binding capacity to
HLA-A3 supertype molecules.
Affinities highlighted in blue
possess an IC50<50 nM. Those
affinities in the 50–500-nM
range are highlighted in
green. Dashes indicate binding
affinity >20,000 nM
Immunogenetics (2011) 63:275–290 285Although Mamu-A1*02601 displays functional analogy to
HLA-A2 supertype alleles and Mamu-B*08301 is associated
with an HLA-A3 supertype peptide specificity, these Mamu
alleles cluster separately from their respective HLA-A2 and
HLA-A3 molecules (Fig. 8). Previous analysis of Mamu-
A1*02201 showed a similar lack of sequence homology to
its functional HLA cognate (Solomon et al. 2010). These
results further support the hypothesis that these shared
similarities in allele specificity have evolved independently
in humans and macaques, most likely as a result of
convergent evolution (Sette and Sidney 1999).
Discussion
Herein we report the peptide-binding motifs associated with
the common Chinese-origin rhesus macaque class I
molecules Mamu-A1*02601 and Mamu-B*08301. This is
Mamu
MHC-A
HLA-A
Mamu
MHC-B
HLA-B
Ch-B*08301 
Ch-A1*02601 
HLA-A2
HLA-A3
Fig. 8 Phylogenetic tree of
HLA and Mamu MHC class I
sequences. Phylogenetic analy-
sis of 22 HLA, 14 Indian rhesus,
and 14 Chinese rhesus MHC
class I sequences is shown.
Neighbor-joining tree created
based on 1,068 aligned nucleo-
tide sites. The percentage of
bootstrap samples supporting
the branch is shown (for values
>50%). Mamu sequences
derived from Indian animals are
prepended with In. Sequences
identified in Chinese animals
(Solomon et al. 2010) are
prepended with Ch. The Mamu
allele B*08301 demonstrating
HLA-A3-like specificity appears
in the Mamu-B group and not
Mamu-A, indicating this motif
specificity between humans and
macaques likely did not arise
through persistence of a
common allele
286 Immunogenetics (2011) 63:275–290the first description of a motif for Chinese-origin Mamu-B
alleles and only the second motif for Mamu-A alleles, since
until now Mamu-A1*02201 was the only Chinese-origin
MHC molecule for which a peptide-binding motif had been
described (Solomon et al. 2010). Thus, our study triples the
number of alleles for which peptide-binding motifs are
available.
The significance of our study is underscored by the fact
that, while Mamu-A1*02201 is the most frequently
expressed class I allele in Chinese rhesus macaques,
Mamu-A1*02601 is the second most frequent allele and
Mamu-B*08301 is the most frequent Mamu-B allele, a
distinction it shares with six other molecules (Solomon et
al. 2010). These three alleles combined allow for potential
coverage of approximately 20% of Chinese rhesus mac-
aques used in biomedical research, irrespective of the
geographical origin from China, thus significantly enhanc-
ing our knowledge of the functional MHC profile of these
experimental animals.
Unexpectedly, we found that both of these molecules are
associated with motifs that are overlapping with well-
known HLA supermotifs. Specifically, Mamu-A1*02601
shares a high degree of cross-reactivity with the HLA-A2
supertype allele HLA-A*0202, as well as HLA-A*0201
and HLA-A*0203. Mamu-B*08301 is highly cross-reactive
with HLA-A3 supertype alleles HLA-A*3101, HLA-
A*0301, and HLA-A*6801. These results are even more
remarkable in the context of the recently described HLA-
B7 supertype specificity similarity of Mamu-A*02201
(Solomon et al. 2010). HLA-B7, HLA-A3, and HLA-A2
are the three most abundant supertypes in the human
population. Separately, each of these three supertypes
has a phenotypic frequency greater than 42% averaged
across various ethnic groups. When these three super-
types are combined, over 86% of the human population
is covered (Sette and Sidney 1999). Thus, each of the
three common Chinese Mamu class I alleles thus far
investigated are associated with a motif corresponding to
one of the three most common HLA supertypes expressed
in humans. It is possible that cross-reactivity with
additional HLA or Mamu alleles will be identified, thus
increasing the relevance and utility of the assays charac-
terized herein for studies directed toward epitope discovery
and characterization of the immune response to specific
pathogens.
These observed similarities of Mamu with HLA could be
explained by either common ancestry or convergent
evolution (Sette et al. 2003). Previous studies have detected
functional similarities between Mamu and HLA class I
molecules, such as Mamu-B*08 with HLA-B*27 mole-
cules. Notably, other similarities like Mamu-A*11 with
HLA-B*44 and Mamu-A*22 with HLA-B*07 (Dzuris et al.
2000; Sette et al. 2005; Loffredo et al. 2009; Solomon et al.
2010) spanned across loci, arguing against the common
ancestry hypothesis. In this study, we show that a Mamu
molecule encoded by the B locus shares overlapping
binding characteristics with HLA-A alleles, also arguing
against common ancestry. This point was further and more
formally demonstrated by phylogenetic analysis. Indeed,
prior to this study, Mamu class I alleles, regardless of loci,
have been purported to be functional HLA-B analogs only
(Hickman-Miller et al. 2005), with rare associations linked
to HLA-A thus far reported, even at the level of binding
specificity. Our results present evidence of two Mamu class
I molecules that share overlapping binding characteristics
with HLA-A alleles.
The class I loci for both Indian- and Chinese-origin
rhesus macaques are highly polymorphic, though Chinese
alleles appear to be more polymorphic given the allele
frequencies that have emerged in this population (Solomon
et al. 2010). Additionally, the allelic variants are largely
non-overlapping, possibly because of the geographical
distance between India and China resulting in low
probability of genetic exchange as demonstrated by
mitochondrial DNA analysis of captive rhesus macaques
(Kanthaswamy and Smith 2004; Satkoski et al. 2008). In
this respect, the absence of the HLA-A2, HLA-A3, and
HLA-B7 specificities from the seven common Indian
rhesus macaque MHC class I alleles characterized to date
(Loffredo et al. 2007; Knapp et al. 1997; Kaizu et al. 2007)
is intriguing. This occurrence is likely the result of a
combination of factors, including but not limited to a
probable founder effect following the 1978 moratorium on
importation of Indian-origin animals and the consequent
breeding in the USA of captive populations.
Regardless of the evolutionary ramifications of MHC
polymorphism and function, our findings have important
practical implications because of the role of Chinese-origin
rhesus macaques in biomedical research. The presence and
identification of key HLA-like specificities in macaque
populations of Chinese origin provides the scientific
community valuable tools to evaluate disease pathogenesis
and vaccine concepts in a setting more reflective of the
global community, with broader human population coverage
implications.
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